Navigation Links
Milestone Scientific to Announce First Quarter 2008 Results on Thursday, May 15, 2008
Date:5/14/2008

Conference Call Scheduled for Monday, May 19, 2008 at 11:00 AM ET

LIVINGSTON, N.J., May 14 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that the Company will report its financial results for the three months ended March 31, 2008 on Thursday, May 15, 2008.

Milestone will host a teleconference on Monday, May 19, 2008, beginning at 11:00 AM Eastern time, and invites all interested parties to join management in a discussion regarding the Company's financial statements, corporate progress and other meaningful developments. The conference call can be accessed by dialing toll-free 1-800-366-3908. For those unable to participate at that time, a replay of the teleconference can be accessed domestically by dialing 1-800-405-2236 and entering the passcode 11114224#. The replay will be available for 90 days.

About Milestone Scientific Inc.

Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(R) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The STA(TM) System, a computer-controlled local anesthesia delivery (CCLAD) system which uses this technology, provides dentists with audible and visual signals as to in-tissue pressure. Milestone's painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at

SOURCE Milestone Scientific Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
3. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
4. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
5. Smurfit-Stones Hodge, LA, Mill Becomes First to Achieve Safety Milestone
6. Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization
7. Milestone Scientific to Present at the Edgewater Research Investor Conference
8. Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
9. Global Gene Map Clears New Milestone
10. Free Site Offering Patient-Physician Dialog Reaches Milestone
11. Marlo Thomas and St. Jude Childrens Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Mass., (PRWEB) August 28, 2014 BCC ... SURGICAL NAVIGATION SYSTEMS: TECHNOLOGIES AND GLOBAL MARKETS , ... at $419.7 million in 2013. Driven by the need ... by medical tourism in emerging geographies, the market is ... annual growth rate (CAGR) of 8.5% from 2013 through ...
(Date:8/28/2014)... Albany, New York (PRWEB) August 28, 2014 ... is currently perceived with great interest among other healthcare ... due to the high demand in vaccine with respect ... also highly in demand due to an improved understanding ... individuals across the United States. It has led to ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Canadian Linen ... company in North America, today announced the launch of ... makes doing business with Canadian Linen even easier and ... customers to access account information online and better communicate ... portal include the ability to:, , ...
(Date:8/28/2014)... AmeriPride Services, a leading textile services ... launch of its new Customer Portal, an online resource ... more convenient for customers. The industry-leading digital tool allows ... with the company. , Features of the new customer ... Access, download and pay bills online , ...
(Date:8/28/2014)... August 28, 2014 Parker Waichman LLP, ... many years fighting to ensure that the heroes of ... provide coverage to WTC victims who developed 9/11-related cancer ... Government Accountability Office (GAO). According to a statement issued ... the report is entitled “World Trade Center Health Program: ...
Breaking Medicine News(10 mins):Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 3Health News:Canadian Linen and Uniform Service Launches New Customer Portal 2Health News:Canadian Linen and Uniform Service Launches New Customer Portal 3Health News:AmeriPride Services Launches New Customer Portal 2Health News:AmeriPride Services Launches New Customer Portal 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3
... New research challenges the previously held belief that infants' ... new study finds the brain's left hemisphere plays the ... immediately after birth. ,Researchers are using functional ... activity in response to speech. They say this is ...
... try to avoid getting it, but researchers say common cold ... genetically engineer the common cold virus so that //it kills ... They did this by modifying one gene, so the virus ... the activity of another gene to ensure that the virus ...
... Government guidelines on the treatment of asthma have long ... for people with persistent forms of the condition.But reports ... people -- including parents of asthmatic children -- to ... growth retardation in children, weak bones in children and ...
... therapeutic option for patients with complicated type 1 diabetes, ... // Now, a new study finds ... worse survival than patients on the transplant waiting list ... Association supports a pancreatic transplant for patients who have ...
... a vaccine made from the common cold virus may induce ... the Centers for Disease Control and Prevention injected six monkeys ... parts of the SARS coronavirus. A new form of the ... were given a second vaccine 28 days later, and researchers ...
... women with diabetes have a higher risk of depression., ... 60 and 79. The participants were divided //into two ... the second included those without diabetes. Women who did ... groups, based on their levels of insulin resistance. ...
Cached Medicine News:Health News:New Technique to Study Infants Brain. 2Health News:Benefits and Risks of Asthma Treatment Questioned 2Health News:Pancreas Transplant for Diabetics 2
(Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... ADHD Therapeutics to 2020 - Broadened ... to Drive Market Growth despite Patent ... ADHD Therapeutics to ...
(Date:8/28/2014)... Aug. 28, 2014  Critical Process Filtration, Inc. ... today announces the expansion of their Technical Services ... Filtration now offers customers and potential customers services ... filter failure analyses (even for competitor filters) and ... hallmark services of system benchmarking and cost/performance optimization. ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014 Amgen ... of a Biologics License Application (BLA) to the U.S. ... for the treatment of high cholesterol. Evolocumab is an ... subtilisin/kexin type 9 (PCSK9), a protein that reduces the ... "bad" cholesterol, from the blood. 1 ­ ...
Breaking Medicine Technology:ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Critical Process Filtration, Inc. Announces Expanded Technical Services and Validation Support 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... -- American Oriental Bioengineering, Inc. (NYSE: AOB ) ... (the "NYSE") has notified the Company that it is not ... to timely file its Annual Report on Form 10-K with ... rules, when a Company does not comply with annual report ...
...  In conjunction with its first quarter 2012 earnings release (expected to be ... CVD ) is pleased to invite you to listen to its ... on Thursday, May 3, 2012 at 9:00 a.m. ET. , ... and Slide Presentation , , , , When: , , , ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2
... GV is a sterile, non-pyrogenic, transparent ... noninflammatory, high molecular weight (average = ... hyaluronate. Healon GV contains 14 mg/mL ... a physiological sodium chloride-phosphate buffer (pH ...
... PROVISC ophthalmic viscosurgical device ... is characterized by high molecular ... surface tension. It provides excellent ... and is easily removed. It ...
... a product comes along that forever raises ... category. The new StealthStation TREON plus Treatment ... Built on the phenomenal success of the ... system in the worldthe new TREON plus ...
... the DigiCat Imager ("DCI") to provide rapid, ... The DCI can measure the cataract and ... objective, appropriate and timely surgical decision can ... technology is especially useful in todays healthcare ...
Medicine Products: